EORTC Melanoma Group Spring Meeting
March 21 - March 22
Turin, Italy
The EORTC Melanoma Group Spring meeting will be held in Turin, Italy on 21-22 March 2024. It is only open to individual or site staff members of the group.
Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member of the EORTC Melanoma Group, and you have not received the registration link, please contact events@eortc.org.
LOCANDINA-21_22-03-24 (Save The Date)
AGENDA
21.03.24 Time slot |
Topic / Title of presentation | Speaker |
12:30 – 13:15 | Lunch | |
13.00 – 13.15 | Opening cerimonia Welcome and Introduction |
Prof Mario Mandalà Prof Simone Ribero |
13.15 – 13:20 | Introduction to the session of the ECI chairs | Prof Francesca Maria Bosisio |
13:20 – 13:55 | Fertility preservation and pregnancy counseling in patients undergoing systemic therapy for melanoma | Dr Alice Indini |
13:55-14:25 | Patients with T1a melanoma at Critical Structures: Association of Excison Margin Size With Local Recurrence and Survival | Dr Ilaria mattavelli |
14:25-14:55 | The role of microRNA in cutaneous melanoma as diagnostic and prognostic biomarkers | Dr Venturi |
14:55-15:00 | Closing remarks | Prof Francesca Maria Bosisio |
15.00-17.00 | Pathology subgroup | |
15:00-15:05 | Welcome Prof Rebecca Senetta | Prof Daniela Massi |
15:05-15:35 | Stromal cues impact melanoma tropism | Dr Amaya Viros |
15:35-15:50 | Spitz vs. Spitzoid / Meta vs. Deposit? | Dr. Anna Szumera-Ciećkiewicz |
15:50-16:05 | Melanoma in Biella: consideration about one year’s experience | Dr Alberto Pisacane |
16:05-16:20 | Genomics and transcriptomics elucidate the ICI response of an NF1-driven anorectal melanoma | Dr Enrico Berrino |
16:20-16:35 | Sex-specific prognostic biomarkers in early-stage melanoma | Dr Giovanna Chiorino |
16:35-16.55 | Lecture | Prof Raymond Barnhill |
16:55-17:00 | Closing remarks | Prof Rebecca Senetta Prof Daniela Massi |
17:00-19:00 | Steering Committee Meeting | |
20:00-22:00 | Dinner Circolo dei lettori Via Bogino 9 |
22.03.24 Time slot |
Topic / Title of presentation | Speaker |
08.50-08.55
|
Opening Cerimonia
|
Prof Mario Mandalà
Prof Bastian Schilling
|
08.55-09.00
|
Lecture introduction
|
Prof Pietro Quaglino
|
09.00-09.30
|
Lecture: RESISTANCE TO TARGETED THERAPY AND IMMUNOTHERAPY IN MELANOMA
|
Prof Dario Sangiolo |
09.30-09:35
|
Early Career Investigators’ (ECI-M) Meeting – Welcome | Prof Francesca Maria Bosisio |
09:35-09:50
|
Real-world outcomes of adjuvant therapy in melanoma: the Turin experience at 4 years | Dr Gabriele Roccuzzo |
09:50-10:05
|
Adjuvant therapy for stage III melanoma: correlation of pathological and molecular characteristics with survival outcomes | Dr Tagliatela Ida |
10:05-10:20
|
LDH isoforms in stage III and stage IV melanoma: and underestimated prognostic biomarker | Dr Laura Soumoy |
10.20-10.50
|
Break | |
10.50 -11.05
|
Prediction of malignant potential of Ambiguous MELanocytic skin lesions based on whole genome copy number Analysis (AMELA) | Dr Hanne Goris |
11:05-11:20
|
Initial results of CAcTUS: A biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted and immune therapy in patients with advanced cutaneous melanoma
|
Dr Rebecca Lee |
11:20-11:35
|
Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma | Dr Oliver Kennedy |
11:35-11:50
|
Long-term efficacy of perioperative therapy in borderline resectable III B-D and IV melanoma | Dr Anna M. Czarnecka |
11:50-11:55
|
Concluding remarks | Prof Francesca Maria Bosisio |
11.55-12.00
|
Lecture introduction
|
Prof Mario Mandalà
|
12.00-12.30
|
Lecture: A brief history of an EORTC statistician
|
Dr Stefan Suciu
|
12.30-13.45
|
Lunch
|
|
14.00-14.50
|
New study proposals
|
Prof Paul Nathan
Prof Bastian Schilling
|
14.00-14.05 | Introduction | Prof Paul Nathan |
14.05-14.25
|
Observational Trial of Sequencing Targeted Therapy and Immune-Checkpoint Inhibition in BRAF Mutant Metastatic Melanoma (liquidSWITCH)
|
Prof Christoffer Gebhardt
|
14.25-14.45
|
NeoMEL (Neoadjuvant immunotherapy in MELanoma) schema
|
Dr Brent O’Carrigan
|
14.45-14.50
|
Concluding remarks
|
Prof Paul Nathan
Prof Mario Mandalà
|
14.50-15.00
|
Break
|
|
15.00-15.45
|
Updates of EORTC clinical trials
|
Prof Bastian Schilling
Prof Mario Mandalà
|
15.00-15.15
|
1612-EBIN: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF-V600 mutation: an EORTC randomized phase II study
|
Prof Caroline Robert
|
15.15-15.30
|
1208-Minitub: Prospective registry on Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissections (CLND) or Nodal Observation
|
Prof Alexander van Akkooi
|
15.30-15.45
|
2022-ATOM: Adjuvant Tebentafusp (IMCgp100) versus observation in HLA-A*0201 positive patients following definitive treatment of high-risk uveal melanoma (UM): a randomized Phase III study.
|
Prof Paul Nathan
|
15.45-16.00
|
Meeting Closure
|
Prof Pietro Quaglino
Prof Mario Mandalà
|
VENUE
NH Collection Torino Piazza Carlina
15 Piazza Carlo Emanuele II
10123 Turin
Italy
Booking accommodation in the meeting venue (NH Collection Torino Piazza Carlina) is possible through this link until 20 February 2024.
Alternative accommodation is possible in Hotel Victoria Torino by completing and returning this form to the hotel.
Next events
EORTC Head and Neck Cancer Group Spring Meeting
April 26 - April 27
Hamburg, DE
ESTRO 2024
May 3 - May 7
Glasgow
EORTC Lung Cancer Group Spring Meeting
May 16 - May 18
Malaga, Spain
EORTC Gynecological Cancer Group Spring Meeting
May 16 - May 17
Barcelona, Spain
EORTC Genito-Urinary Cancer Group Spring Meeting
May 17
Barcelona, Spain